Evaluating AI's Potential Impact on Biopharma

BlackRock explores how AI is reshaping the biopharma industry by accelerating drug discovery, reducing high R&D failure rates, and increasing the Net Present Value of pharmaceutical assets.

Key Takeaways

• 1.The AI market in the pharmaceutical industry is projected to grow from USD $4.4 billion to $25.7 billion by 2030.
• 2.AI addresses critical biopharma inefficiencies, including the 90% drug failure rate and the 13-15 year development timeline.
• 3.Shortening drug development timelines through AI could increase Net Present Value (NPV) per drug by 25-30%.

Table of Contents

• Why is Biopharma primed for AI enablement?
• Problems Biopharma Industry Faces Today
• Al across the BioPharma value chain
• AI Driven Improvements In action
• Key Regulatory Developments
• Notable Technology Partnerships & Developments
• BlackRock Health Sciences

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial